Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis

AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France. julien.lopinto@aphp.fr. AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France. Univ Paris Est Creteil, INSERM, IMRB, FHU SENEC, Creteil, F-94010, France; Univ paris Est Creteil, Centre de reference des Syndrome drepanocytaire Majeurs, Unite des Maladies Genetiques du Globule Rouge (UMGGR). AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, F-94010, Creteil, France; Univ Paris Est Creteil, CARMAS, Creteil, F-94010, France; Univ Paris Est Creteil, INSERM, IMRB, FHU SENEC, Creteil, F-94010, France.

Haematologica. 2022
Full text from:
Abstract
Whether corticosteroids improve outcome in patients with acute complications of sickle cell disease (SCD) is still debated. We performed a systematic review of the literature with the aim of estimating effects of corticosteroids on the clinical course of vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) in patients with SCD. The primary outcome was transfusion requirement during hospitalization. Studies were identified by search of MEDLINE and CENTRAL database. Three randomized clinical trials (RCT) and three retrospective cohort studies (RCS) were included, involving 3,304 participants and 5,562 VOC or ACS episodes. There was no difference between corticosteroids and standard treatment regarding transfusion overall [OR=0.98 (95% CI 0.38 to 2.53)], but with a significant interaction of study type (P.
Study details
Study Design : Systematic Review
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine